

# PRIOR AUTHORIZATION CRITERIA

**BRAND NAME**  
(generic)

**EMSAM**  
(selegiline)

**Status: CVS Caremark Criteria**

**Type: Initial Prior Authorization**

**Ref # 867-A**

## POLICY

### FDA-APPROVED INDICATIONS

Emsam (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD).

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for an adult patient for the treatment of major depressive disorder (MDD)
- AND**
- The patient will be monitored closely for suicidal thoughts and behavior and clinical worsening
- AND**
- The patient experienced an inadequate treatment response, intolerance, or contraindication to any of the following antidepressants: A) bupropion, trazodone, mirtazapine, B) serotonin norepinephrine reuptake inhibitors (e.g., venlafaxine), C) selective serotonin reuptake inhibitors (e.g., citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), D) tricyclic or tetracyclic antidepressants (e.g., amitriptyline, nortriptyline)
- OR**
- The patient is unable to swallow oral formulations

### REFERENCES

1. Emsam [package insert]. Morgantown, WV: Somerset Pharmaceuticals, Inc.; July 2017.
2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; [http://online.lexi.com/lco/action/index/dataset/complete\\_ashp](http://online.lexi.com/lco/action/index/dataset/complete_ashp) [available with subscription]. Accessed May 2018.
3. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. [www.micromedexsolutions.com](http://www.micromedexsolutions.com) [available with subscription]. Accessed May 2018.
4. Trangle M, Gursky J, Haight R, et al. Institute for Clinical Systems Improvement. Adult Depression in Primary Care. Updated March 2016.
5. Gelenberg A, Freeman M, Markowitz J, et al. Practice Guideline for the Treatment of Patients With Major Depressive Disorder Third Edition (November 2010). <http://psychiatryonline.org/guidelines.aspx>. Accessed May 2018.